PARP1 and neoplasm: To validate the anti-tumor activities of these hit compounds of PARP-1, HCT-116 (BRCA-deficient colorectal carcinoma cells), RKO (BRCA-proficient colorectal carcinoma cells) were applied for the cell survival assay.